• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

“预演”分析:一种评估混杂因素控制风险评分的方法。

The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control.

作者信息

Wyss Richard, Hansen Ben B, Ellis Alan R, Gagne Joshua J, Desai Rishi J, Glynn Robert J, Stürmer Til

出版信息

Am J Epidemiol. 2017 May 1;185(9):842-852. doi: 10.1093/aje/kwx032.

DOI:10.1093/aje/kwx032
PMID:28338910
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5411679/
Abstract

A propensity score (PS) model's ability to control confounding can be assessed by evaluating covariate balance across exposure groups after PS adjustment. The optimal strategy for evaluating a disease risk score (DRS) model's ability to control confounding is less clear. DRS models cannot be evaluated through balance checks within the full population, and they are usually assessed through prediction diagnostics and goodness-of-fit tests. A proposed alternative is the "dry-run" analysis, which divides the unexposed population into "pseudo-exposed" and "pseudo-unexposed" groups so that differences on observed covariates resemble differences between the actual exposed and unexposed populations. With no exposure effect separating the pseudo-exposed and pseudo-unexposed groups, a DRS model is evaluated by its ability to retrieve an unconfounded null estimate after adjustment in this pseudo-population. We used simulations and an empirical example to compare traditional DRS performance metrics with the dry-run validation. In simulations, the dry run often improved assessment of confounding control, compared with the C statistic and goodness-of-fit tests. In the empirical example, PS and DRS matching gave similar results and showed good performance in terms of covariate balance (PS matching) and controlling confounding in the dry-run analysis (DRS matching). The dry-run analysis may prove useful in evaluating confounding control through DRS models.

摘要

倾向评分(PS)模型控制混杂因素的能力可通过评估PS调整后各暴露组间的协变量平衡来进行评估。评估疾病风险评分(DRS)模型控制混杂因素能力的最佳策略尚不太明确。DRS模型无法通过在整个人口中进行平衡检查来评估,通常通过预测诊断和拟合优度检验来评估。一种提议的替代方法是“预演”分析,即将未暴露人群分为“假暴露”和“假未暴露”组,以使观察到的协变量差异类似于实际暴露和未暴露人群之间的差异。由于没有暴露效应来区分假暴露组和假未暴露组,因此通过DRS模型在这个假人群中调整后检索无混杂零估计值的能力来评估该模型。我们使用模拟和一个实证例子,将传统的DRS性能指标与预演验证进行比较。在模拟中,与C统计量和拟合优度检验相比,预演通常能改善对混杂控制的评估。在实证例子中,PS匹配和DRS匹配给出了相似的结果,并且在协变量平衡(PS匹配)和预演分析中的混杂控制(DRS匹配)方面表现良好。预演分析可能在通过DRS模型评估混杂控制方面被证明是有用的。

相似文献

1
The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control.“预演”分析:一种评估混杂因素控制风险评分的方法。
Am J Epidemiol. 2017 May 1;185(9):842-852. doi: 10.1093/aje/kwx032.
2
Prognostic score-based model averaging approach for propensity score estimation.基于预后评分的模型平均倾向评分估计方法。
BMC Med Res Methodol. 2024 Oct 3;24(1):228. doi: 10.1186/s12874-024-02350-y.
3
Evaluation of propensity scores, disease risk scores, and regression in confounder adjustment for the safety of emerging treatment with group sequential monitoring.在序贯组监测中对新兴治疗安全性进行混杂因素调整时,倾向得分、疾病风险评分及回归的评估。
Pharmacoepidemiol Drug Saf. 2016 Apr;25(4):453-61. doi: 10.1002/pds.3983. Epub 2016 Feb 15.
4
Matching on the disease risk score in comparative effectiveness research of new treatments.在新疗法的比较效果研究中对疾病风险评分进行匹配。
Pharmacoepidemiol Drug Saf. 2015 Sep;24(9):951-61. doi: 10.1002/pds.3810. Epub 2015 Jun 25.
5
Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research.基于预后评分的平衡措施可作为比较有效性研究中倾向评分方法的有用诊断工具。
J Clin Epidemiol. 2013 Aug;66(8 Suppl):S84-S90.e1. doi: 10.1016/j.jclinepi.2013.01.013.
6
Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders.存在多种混杂因素时,疾病风险评分、倾向评分和传统多变量结局回归的表现。
Am J Epidemiol. 2011 Sep 1;174(5):613-20. doi: 10.1093/aje/kwr143. Epub 2011 Jul 12.
7
Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches.口服抗凝剂研究中的混杂因素控制:比较采用不同随访方法得出的疾病风险评分
EGEMS (Wash DC). 2019 Jul 15;7(1):27. doi: 10.5334/egems.254.
8
Extension of Disease Risk Score-Based Confounding Adjustments for Multiple Outcomes of Interest: An Empirical Evaluation.基于疾病风险评分的混杂因素调整对多个感兴趣结局的扩展:一项实证评估。
Am J Epidemiol. 2018 Nov 1;187(11):2439-2448. doi: 10.1093/aje/kwy130.
9
Applied comparison of large-scale propensity score matching and cardinality matching for causal inference in observational research.应用大规模倾向评分匹配和基数匹配在观察性研究中的因果推断的比较。
BMC Med Res Methodol. 2021 May 24;21(1):109. doi: 10.1186/s12874-021-01282-1.
10
On the use and misuse of scalar scores of confounders in design and analysis of observational studies.关于混杂因素标量分数在观察性研究设计与分析中的使用及误用
Stat Med. 2015 Aug 15;34(18):2618-35. doi: 10.1002/sim.6467. Epub 2015 Mar 17.

引用本文的文献

1
Evaluating the Role of High-Dimensional Proxy Data in Confounding Adjustment in Multiple Sclerosis Research: A Case Study.评估高维代理数据在多发性硬化症研究中混杂因素调整中的作用:一项案例研究。
Pharmacoepidemiol Drug Saf. 2025 Feb;34(2):e70112. doi: 10.1002/pds.70112.
2
Methods to Adjust for Confounding in Test-Negative Design COVID-19 Effectiveness Studies: Simulation Study.检测阴性设计的 COVID-19 有效性研究中调整混杂因素的方法:模拟研究
JMIR Form Res. 2025 Jan 27;9:e58981. doi: 10.2196/58981.
3
Favorable changes in the eGFR slope after dapagliflozin treatment and its association with the initial dip.达格列净治疗后估算肾小球滤过率(eGFR)斜率的有利变化及其与初始下降的关联。
Clin Exp Nephrol. 2024 Dec;28(12):1282-1289. doi: 10.1007/s10157-024-02532-4. Epub 2024 Jul 6.
4
Use of clinical pharmacy services by American Indians and Alaska Native adults with cardiovascular disease.患有心血管疾病的美国印第安人和阿拉斯加原住民成年人对临床药学服务的使用情况。
J Am Coll Clin Pharm. 2022 Aug;5(8):800-811. doi: 10.1002/jac5.1651. Epub 2022 May 25.
5
Synthetic Negative Controls: Using Simulation to Screen Large-scale Propensity Score Analyses.合成阴性对照:使用模拟筛选大规模倾向评分分析。
Epidemiology. 2022 Jul 1;33(4):541-550. doi: 10.1097/EDE.0000000000001482. Epub 2022 Apr 12.
6
A likely responder approach for the analysis of randomized controlled trials.可能响应者分析方法在随机对照试验中的应用。
Contemp Clin Trials. 2022 Mar;114:106688. doi: 10.1016/j.cct.2022.106688. Epub 2022 Jan 24.
7
Using Real-World Data to Predict Clinical and Economic Benefits of a Future Drug Based on its Target Product Profile.利用真实世界数据,根据未来药物的目标产品概况预测其临床和经济效益。
Drugs Real World Outcomes. 2020 Sep;7(3):221-227. doi: 10.1007/s40801-020-00203-w.
8
Standardizing Discrete-Time Hazard Ratios With a Disease Risk Score.用疾病风险评分标准化离散时间风险比。
Am J Epidemiol. 2020 Oct 1;189(10):1197-1203. doi: 10.1093/aje/kwaa061.
9
On the aggregation of published prognostic scores for causal inference in observational studies.发表的预后评分在观察性研究中因果推断的聚集。
Stat Med. 2020 May 15;39(10):1440-1457. doi: 10.1002/sim.8489. Epub 2020 Feb 5.
10
Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches.口服抗凝剂研究中的混杂因素控制:比较采用不同随访方法得出的疾病风险评分
EGEMS (Wash DC). 2019 Jul 15;7(1):27. doi: 10.5334/egems.254.

本文引用的文献

1
Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study.达比加群酯或华法林对房颤患者血栓栓塞和大出血结局发生率的预测:新启动治疗队列研究
BMJ. 2016 May 24;353:i2607. doi: 10.1136/bmj.i2607.
2
Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data.历史数据中高维疾病风险评分的降维和收缩方法。
Emerg Themes Epidemiol. 2016 Apr 5;13:5. doi: 10.1186/s12982-016-0047-x. eCollection 2016.
3
Comparison of Calipers for Matching on the Disease Risk Score.用于疾病风险评分匹配的卡尺比较
Am J Epidemiol. 2016 May 15;183(10):937-48. doi: 10.1093/aje/kwv302. Epub 2016 Apr 1.
4
Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications.新上市药物比较研究中高维混杂因素汇总分数的比较
J Clin Epidemiol. 2016 Aug;76:200-8. doi: 10.1016/j.jclinepi.2016.02.011. Epub 2016 Feb 27.
5
Matching on the disease risk score in comparative effectiveness research of new treatments.在新疗法的比较效果研究中对疾病风险评分进行匹配。
Pharmacoepidemiol Drug Saf. 2015 Sep;24(9):951-61. doi: 10.1002/pds.3810. Epub 2015 Jun 25.
6
A new weighted balance measure helped to select the variables to be included in a propensity score model.一种新的加权平衡度量方法有助于选择要包含在倾向评分模型中的变量。
J Clin Epidemiol. 2015 Dec;68(12):1415-22.e2. doi: 10.1016/j.jclinepi.2015.04.009. Epub 2015 May 1.
7
Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.达比加群酯与华法林在美国非瓣膜性心房颤动真实世界患者中的有效性和安全性:一项回顾性队列研究。
J Am Heart Assoc. 2015 Apr 10;4(4):e001798. doi: 10.1161/JAHA.115.001798.
8
Reducing Bias Amplification in the Presence of Unmeasured Confounding Through Out-of-Sample Estimation Strategies for the Disease Risk Score.通过疾病风险评分的样本外估计策略减少未测量混杂因素存在时的偏差放大。
J Causal Inference. 2014 Sep 1;2(2):131-146. doi: 10.1515/jci-2014-0009.
9
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.房颤患者口服抗凝剂起始治疗的模式-质量和成本影响。
Am J Med. 2014 Nov;127(11):1075-1082.e1. doi: 10.1016/j.amjmed.2014.05.013. Epub 2014 May 21.
10
Commentary: Balancing automated procedures for confounding control with background knowledge.评论:平衡用于混杂因素控制的自动化程序与背景知识。
Epidemiology. 2014 Mar;25(2):279-81. doi: 10.1097/EDE.0000000000000068.